Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD9592 Monotherapy and Combination Therapy in Advanced Solid Tumors
NCT05647122Phase 1Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2022
- Primary completion
- Jun 2026
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 11
01
Overview
Phase 1 trial of tilatamig samrotecan, sponsored by AstraZeneca. Started Dec 2022; status: active, not recruiting.
02
Drugs
tilatamig samrotecan
Beyond the preview
Go deeper on NCT05647122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05647122.